GLP1R and metabolic dysfunction-associated steatohepatitis: GLP-1R agonists further attenuate hepatic steatosis and inflammation in models of non-alcoholic steatohepatitis (NASH), alleviating hepatocyte injury (Nevola et al., 2023).